Orphan designation: Cannabidiol, Treatment of epilepsy with myoclonic-atonic seizures, 13/04/2022, Positive
This medicine was designated as an orphan medicine for the treatment of epilepsy with myoclonic-atonic seizures in the European Union on 13 April 2022. This means that the developer will receive scientific and regulatory support from EMA to advance their …